@storyperch1
Active 3 months, 1 week ago
We thank Dr. Evangelatos for his interest in the guideline and his efforts to provide further clarity to this clinical scenario. During the guideline process, the voting panel thoroughly discussed many of these aspects of hypogammaglobulinemia during rituximab treatment that Dr. Evangelatos has adeptly described.
To evaluate seroreactivity […] View
-
Robles Kern posted an update 3 months, 1 week ago
We thank Dr. Evangelatos for his interest in the guideline and his efforts to provide further clarity to this clinical scenario. During the guideline process, the voting panel thoroughly discussed many of these aspects of hypogammaglobulinemia during rituximab treatment that Dr. Evangelatos has adeptly described.
To evaluate seroreactivity and…[Read more]
-
Robles Kern became a registered member 3 months, 1 week ago
